Innovent Biologics Inc Net Assets
Innovent Biologics Inc net assets. Based on the latest financial reports, Innovent Biologics Inc (6IB) has net assets worth €19.36 Billion EUR (≈ $22.63 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€37.35 Billion ≈ $43.66 Billion USD) and total liabilities (€17.99 Billion ≈ $21.03 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 6IB shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €19.36 Billion |
| % of Total Assets | 51.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | 87.37% |
| 10-Year Change | N/A |
| Growth Volatility | 27.12 |
Net Assets of Innovent Biologics Inc (2016–2025)
Net assets of Innovent Biologics Inc from 2016 to 2025. This chart illustrates how Innovent Biologics Inc's net assets have evolved over time, based on quarterly financial data. See 6IB equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Innovent Biologics Inc (2016–2025)
The table below shows the annual net assets of Innovent Biologics Inc from 2016 to 2025. For live market cap and overall valuation, see market value of Innovent Biologics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €19.36 Billion ≈ $22.63 Billion |
+47.56% |
| 2024-12-31 | €13.12 Billion ≈ $15.34 Billion |
+4.71% |
| 2023-12-31 | €12.53 Billion ≈ $14.65 Billion |
+16.75% |
| 2022-12-31 | €10.73 Billion ≈ $12.54 Billion |
+3.87% |
| 2021-12-31 | €10.33 Billion ≈ $12.08 Billion |
+17.66% |
| 2020-12-31 | €8.78 Billion ≈ $10.26 Billion |
+84.60% |
| 2019-12-31 | €4.76 Billion ≈ $5.56 Billion |
+13.39% |
| 2018-12-31 | €4.19 Billion ≈ $4.90 Billion |
+358.57% |
| 2017-12-31 | €-1.62 Billion ≈ $-1.90 Billion |
-69.29% |
| 2016-12-31 | €-958.22 Million ≈ $-1.12 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Innovent Biologics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1416299500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Innovent Biologics Inc Net Assets Breakdown (December 2025)
Innovent Biologics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €34.45 Billion | 177.97% |
| Total Equity | €19.36 Billion | 100.00% |
Innovent Biologics Inc Competitors by Market Cap
The table below lists competitors of Innovent Biologics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OMV AG ADR 1
F:OMVI
|
$18.00 Billion |
|
SBI Life Insurance Company Limited
NSE:SBILIFE
|
$18.00 Billion |
|
Suncorp Group Ltd
AU:SUNPH
|
$18.01 Billion |
|
Banco Do Brasil SA
F:BZLA
|
$18.02 Billion |
|
Evergreen Marine Corp Taiwan Ltd
TW:2603
|
$17.94 Billion |
|
East West Bancorp Inc
NASDAQ:EWBC
|
$17.92 Billion |
|
MACOM Technology Solutions Holdings Inc
NASDAQ:MTSI
|
$17.90 Billion |
|
Lundin Mining Corporation
TO:LUN
|
$17.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innovent Biologics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,117,729,000 to 19,356,243,000, a change of 6,238,514,000 (47.6%).
- Net income of 813,565,000 contributed positively to equity growth.
- New share issuances of 4,718,755,000 increased equity.
- Other factors increased equity by 706,194,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €813.57 Million | +4.2% |
| Share Issuances | €4.72 Billion | +24.38% |
| Other Changes | €706.19 Million | +3.65% |
| Total Change | €- | 47.56% |
Book Value vs Market Value Analysis
This analysis compares Innovent Biologics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.82x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €-1.74 | €9.16 | x |
| 2018-12-31 | €3.64 | €9.16 | x |
| 2019-12-31 | €3.77 | €9.16 | x |
| 2020-12-31 | €6.26 | €9.16 | x |
| 2021-12-31 | €7.07 | €9.16 | x |
| 2022-12-31 | €6.99 | €9.16 | x |
| 2023-12-31 | €7.72 | €9.16 | x |
| 2024-12-31 | €8.01 | €9.16 | x |
| 2025-12-31 | €11.16 | €9.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innovent Biologics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.24%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.93x
- Recent ROE (4.20%) is above the historical average (-24.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | €-365.81 Million |
| 2017 | 0.00% | -3033.33% | 0.01x | 0.00x | €-368.06 Million |
| 2018 | -137.60% | -60899.99% | 0.00x | 1.46x | €-6.19 Billion |
| 2019 | -36.16% | -164.19% | 0.14x | 1.52x | €-2.20 Billion |
| 2020 | -11.37% | -25.97% | 0.32x | 1.35x | €-1.88 Billion |
| 2021 | -30.38% | -73.50% | 0.26x | 1.57x | €-4.17 Billion |
| 2022 | -20.31% | -47.83% | 0.26x | 1.64x | €-3.25 Billion |
| 2023 | -8.21% | -16.56% | 0.30x | 1.65x | €-2.28 Billion |
| 2024 | -0.72% | -1.00% | 0.44x | 1.65x | €-1.41 Billion |
| 2025 | 4.20% | 6.24% | 0.35x | 1.93x | €-1.12 Billion |
Industry Comparison
This section compares Innovent Biologics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $380,407,590
- Average return on equity (ROE) among peers: -34.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innovent Biologics Inc (6IB) | €19.36 Billion | 0.00% | 0.93x | $17.98 Billion |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-1.58 Million | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $144.67 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $696.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, a… Read more